Stereotactic body radiation therapy for primary lung cancers clinically diagnosed without pathological confirmation

a single-institution experience

Tadamasa Yoshitake, Katsumasa Nakamura, Yoshiyuki Shioyama, Tomonari Sasaki, Ohga Saiji, Makoto Shinoto, Kotaro Terashima, Kaori Asai, Keiji Matsumoto, Yoshio Matsuo, Shingo Baba, Hiroshi Honda

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Pathological diagnosis of small lung lesions is sometimes difficult in medically inoperable patients. The purpose of this study was to evaluate the adverse events and the outcomes of stereotactic body radiation therapy (SBRT) for lung lesions which were clinically diagnosed as primary lung cancer without pathological confirmation. Methods: Between April 2003 and April 2011, 88 patients with small lung lesions which were clinically diagnosed as primary lung cancer were treated with SBRT. The median tumor size was 19 mm (range 8–40 mm). The radiation dose was 48 Gy in four fractions in all patients. The median follow-up was 23 months (range 6–91 months). Results: Recurrence was observed in 13 patients. The local control rate, progression-free survival rate, and overall survival rate at 3 years were 90, 67, and 80 %, respectively. Two patients (2.3 %) had Grade 2 radiation pneumonitis, and six patients (6.8 %) had Grade 2 rib fractures. There were no adverse events of Grade 3 or greater. Conclusions: SBRT appears to be a safe and effective treatment option for small lung lesions that are clinically diagnosed as primary lung cancer without pathological confirmation.

Original languageEnglish
Pages (from-to)53-58
Number of pages6
JournalInternational Journal of Clinical Oncology
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Lung Neoplasms
Radiotherapy
Lung
Survival Rate
Radiation Pneumonitis
Rib Fractures
Disease-Free Survival
Radiation
Recurrence
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Cite this

Stereotactic body radiation therapy for primary lung cancers clinically diagnosed without pathological confirmation : a single-institution experience. / Yoshitake, Tadamasa; Nakamura, Katsumasa; Shioyama, Yoshiyuki; Sasaki, Tomonari; Saiji, Ohga; Shinoto, Makoto; Terashima, Kotaro; Asai, Kaori; Matsumoto, Keiji; Matsuo, Yoshio; Baba, Shingo; Honda, Hiroshi.

In: International Journal of Clinical Oncology, Vol. 20, No. 1, 01.01.2015, p. 53-58.

Research output: Contribution to journalArticle

@article{76b2935f36944d1597b555f8dd9c0cd1,
title = "Stereotactic body radiation therapy for primary lung cancers clinically diagnosed without pathological confirmation: a single-institution experience",
abstract = "Background: Pathological diagnosis of small lung lesions is sometimes difficult in medically inoperable patients. The purpose of this study was to evaluate the adverse events and the outcomes of stereotactic body radiation therapy (SBRT) for lung lesions which were clinically diagnosed as primary lung cancer without pathological confirmation. Methods: Between April 2003 and April 2011, 88 patients with small lung lesions which were clinically diagnosed as primary lung cancer were treated with SBRT. The median tumor size was 19 mm (range 8–40 mm). The radiation dose was 48 Gy in four fractions in all patients. The median follow-up was 23 months (range 6–91 months). Results: Recurrence was observed in 13 patients. The local control rate, progression-free survival rate, and overall survival rate at 3 years were 90, 67, and 80 {\%}, respectively. Two patients (2.3 {\%}) had Grade 2 radiation pneumonitis, and six patients (6.8 {\%}) had Grade 2 rib fractures. There were no adverse events of Grade 3 or greater. Conclusions: SBRT appears to be a safe and effective treatment option for small lung lesions that are clinically diagnosed as primary lung cancer without pathological confirmation.",
author = "Tadamasa Yoshitake and Katsumasa Nakamura and Yoshiyuki Shioyama and Tomonari Sasaki and Ohga Saiji and Makoto Shinoto and Kotaro Terashima and Kaori Asai and Keiji Matsumoto and Yoshio Matsuo and Shingo Baba and Hiroshi Honda",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s10147-014-0698-y",
language = "English",
volume = "20",
pages = "53--58",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Stereotactic body radiation therapy for primary lung cancers clinically diagnosed without pathological confirmation

T2 - a single-institution experience

AU - Yoshitake, Tadamasa

AU - Nakamura, Katsumasa

AU - Shioyama, Yoshiyuki

AU - Sasaki, Tomonari

AU - Saiji, Ohga

AU - Shinoto, Makoto

AU - Terashima, Kotaro

AU - Asai, Kaori

AU - Matsumoto, Keiji

AU - Matsuo, Yoshio

AU - Baba, Shingo

AU - Honda, Hiroshi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Pathological diagnosis of small lung lesions is sometimes difficult in medically inoperable patients. The purpose of this study was to evaluate the adverse events and the outcomes of stereotactic body radiation therapy (SBRT) for lung lesions which were clinically diagnosed as primary lung cancer without pathological confirmation. Methods: Between April 2003 and April 2011, 88 patients with small lung lesions which were clinically diagnosed as primary lung cancer were treated with SBRT. The median tumor size was 19 mm (range 8–40 mm). The radiation dose was 48 Gy in four fractions in all patients. The median follow-up was 23 months (range 6–91 months). Results: Recurrence was observed in 13 patients. The local control rate, progression-free survival rate, and overall survival rate at 3 years were 90, 67, and 80 %, respectively. Two patients (2.3 %) had Grade 2 radiation pneumonitis, and six patients (6.8 %) had Grade 2 rib fractures. There were no adverse events of Grade 3 or greater. Conclusions: SBRT appears to be a safe and effective treatment option for small lung lesions that are clinically diagnosed as primary lung cancer without pathological confirmation.

AB - Background: Pathological diagnosis of small lung lesions is sometimes difficult in medically inoperable patients. The purpose of this study was to evaluate the adverse events and the outcomes of stereotactic body radiation therapy (SBRT) for lung lesions which were clinically diagnosed as primary lung cancer without pathological confirmation. Methods: Between April 2003 and April 2011, 88 patients with small lung lesions which were clinically diagnosed as primary lung cancer were treated with SBRT. The median tumor size was 19 mm (range 8–40 mm). The radiation dose was 48 Gy in four fractions in all patients. The median follow-up was 23 months (range 6–91 months). Results: Recurrence was observed in 13 patients. The local control rate, progression-free survival rate, and overall survival rate at 3 years were 90, 67, and 80 %, respectively. Two patients (2.3 %) had Grade 2 radiation pneumonitis, and six patients (6.8 %) had Grade 2 rib fractures. There were no adverse events of Grade 3 or greater. Conclusions: SBRT appears to be a safe and effective treatment option for small lung lesions that are clinically diagnosed as primary lung cancer without pathological confirmation.

UR - http://www.scopus.com/inward/record.url?scp=84939880130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939880130&partnerID=8YFLogxK

U2 - 10.1007/s10147-014-0698-y

DO - 10.1007/s10147-014-0698-y

M3 - Article

VL - 20

SP - 53

EP - 58

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 1

ER -